- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07638449
Silkworm Pupa Powder Improves Alzheimer's Disease
A Prospective, Single-Arm Study Evaluating Silkworm Pupa Powder in Improving Alzheimer's Disease Among Patients
The goal of this clinical trial is to learn if silkworm pupa powder works to treat Alzheimer's disease in patients. It will also learn about the safety of silkworm pupa powder, and its effect on patients' nutritional and frailty status. The main questions it aims to answer are:
- Does silkworm pupa powder improve cognitive function and daily living abilities?
- Does silkworm pupa powder improve nutritional status and frailty?
- What medical problems do participants have when taking silkworm pupa powder?
Researchers will evaluate the treatment by comparing the participants' conditions after taking the powder to their baseline conditions (a single-arm study without a placebo) to see if silkworm pupa powder works to treat Alzheimer's disease.
Participants will:
- Take silkworm pupa powder every day for 12 weeks
- Visit the clinic once every 4 weeks for checkups and tests
- Use an electronic punch-card system daily and report any symptoms
A tanulmány áttekintése
Állapot
Körülmények
Beavatkozás / kezelés
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Jiangtao Zhang
- Telefonszám: +8618969125501
- E-mail: 18969125501@163.com
Tanulmányi helyek
-
-
Zhejiang
-
Hangzhou, Zhejiang, Kína, 310012
- Tongde Hospital of Zhejiang Province
-
Kapcsolatba lépni:
- Jiangtao Zhang, Phd
- Telefonszám: 8618969125501
- E-mail: 18969125501@163.com
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
- Idősebb felnőtt
Egészséges önkénteseket fogad
Leírás
Inclusion Criteria:
- Diagnosis of probable Alzheimer's disease (AD) according to the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria. Disease severity is classified as mild to moderate, defined as a Mini-Mental State Examination (MMSE) total score of 0-24 points, inclusive, at both screening and baseline.
- Confirmation of AD pathology per the 2024 revised AD diagnostic criteria (biomarker-defined AD with both Aβ and tau positivity):
- Aβ positivity: Plasma Aβ42/40 ratio ≤0.08 or amyloid-PET positivity (SUVR ≥1.1).
- Tau positivity: Plasma p-tau217 ≥2.5 pg/mL (or CSF p-tau181/Aβ42 ratio ≥0.02).
- Age 50 to 90 years (inclusive), male or female, with at least a primary school education.
- Stable medication use: If receiving approved AD therapies (e.g., acetylcholinesterase inhibitors, GV-971, NMDA receptor antagonists), doses must remain stable for ≥12 weeks prior to baseline. Treatment-naïve participants are also eligible. All other permitted non-AD related concomitant medications must remain stable for ≥4 weeks prior to baseline unless otherwise specified.
- Hachinski Ischemia Scale (HIS) total score ≤4.
- Geriatric Depression Scale-15 (GDS-15) total score ≤4.
- Neuroimaging evidence: Screening CT/MRI showing age-related brain changes or cerebral atrophy.
- Participant has a stable and reliable caregiver, as confirmed by the investigator.
- Written informed consent must be provided by the participant or, if the participant lacks decision-making capacity, by a legally authorized representative (in accordance with local laws, regulations, and customs). Participants must agree to provide peripheral blood, stool, and urine samples during the study for biomarker analysis.
Exclusion Criteria:
- Diagnosis of dementia other than Alzheimer's disease (AD) or other central nervous system disorders.
- Unstable vital signs accompanied by abnormalities in cardiac, pulmonary, hepatic, renal, or other organ functions.
- Abnormally low folate and/or vitamin B12 levels, or evidence that hypothyroidism has caused or exacerbated the participant's dementia. Abnormal syphilis test results.
- Comorbid psychiatric disorders.
- Long-term alcoholism or substance abuse that may compromise the evaluation of treatment efficacy.
- Intolerance or allergy to the study medication (silkworm pupa powder).
- Abnormalities detected on cranial MRI, including ischemic or hemorrhagic infarctions, hydrocephalus, or brain tumors.
- Diagnosis of clinically significant cardiovascular or cerebrovascular disease requiring treatment within 12 months or at present.
- Geriatric Depression Scale-15 (GDS-15) score >4 at screening.
- Any other inadequately controlled condition (e.g., cardiac, respiratory, renal, or gastrointestinal disorders affecting absorption, such as gastric cancer, gastric bypass surgery, or recurrent diarrhea) that may jeopardize participant safety or interfere with study assessments, as judged by the investigator.
- Administration of any new chemical entity in an AD clinical study within 6 months prior to screening.
- Clinically significant abnormalities in physical examination, vital signs, laboratory tests, or electrocardiogram (ECG) requiring further investigation, treatment, or posing risks to study procedures or safety.
- Participation in a clinical study involving therapeutic monoclonal antibodies, antibody-derived proteins, immunoglobulin therapy, or vaccines within 6 months prior to screening.
- Participation in a clinical study involving any anti-amyloid therapies (including any monoclonal antibody therapy and any BACE inhibitor therapy).
- Any inadequately controlled immune disorder, or immune disease requiring treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives), systemic immunosuppressants, or plasmapheresis during the study.
- Inadequately controlled bleeding disorders (including platelet count <50,000 or INR >1.5 for participants not on anticoagulants, e.g., warfarin). Participants on anticoagulants must have their anticoagulation status optimized and receive a stable dose within 4 weeks prior to screening. Participants receiving anticoagulant therapy must not participate in cerebrospinal fluid (CSF) assessments.
- Participation in another concurrent silkworm pupa powder intervention study conducted at the same study center.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Kezelés
- Kiosztás: N/A
- Beavatkozó modell: Egyetlen csoportos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: Group
Silkworm pupa powder, 2 times a day, two packets (12*2 g) each time, take with warm water, before meals, for three months
|
Selyemhernyó bábpor, naponta 2x, két csomag (12*2 g) minden alkalommal, étkezés előtt, meleg vízzel, három hónapig
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Alzheimer -kóros betegség -értékelési skála - kognitív alskála (ADAS -COG)
Időkeret: A selyemhernyó bevétele után a 0. 、 4. 、 8. és 12. hét
|
Az ADAS-COG egy olyan eszköz, amelynek célja az Alzheimer-kórban szenvedő betegek kognitív károsodásának súlyosságának felmérése.
12 elemből áll, amelyek több kognitív tartományt értékelnek, beleértve a memóriát, az orientációt, a nyelvet, a gyakorlatot (gyakorlati képesség), a figyelmet és mások.
A szabványosított kognitív feladatok sorozatán keresztül méri az AD-vel kapcsolatos kognitív tünetek súlyosságát, és nyomon követi a kezelésre adott válasz változását.
A magasabb pontszámok súlyosabb kognitív károsodást jeleznek.
|
A selyemhernyó bevétele után a 0. 、 4. 、 8. és 12. hét
|
|
Bilateral Hippocampal Volume
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Bilateral hippocampal volume will be measured using 3.0T structural MRI T1-weighted imaging.
Lower hippocampal volume indicates greater AD-related brain atrophy.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Entorhinal Cortex Volume
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Entorhinal cortex volume will be measured using 3.0T structural MRI T1-weighted imaging.
Lower volume indicates greater AD-related brain atrophy.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Temporoparietal Regional Volume
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Temporoparietal regional volume will be measured using 3.0T structural MRI T1-weighted imaging.
Lower volume indicates greater AD-related brain atrophy.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Cortical Thickness of AD-Related Brain Regions
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Cortical thickness in AD-related brain regions, including the entorhinal cortex and temporoparietal cortex, will be measured using 3.0T structural MRI.
Lower cortical thickness indicates greater cortical atrophy.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Fractional Anisotropy
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Fractional anisotropy will be measured using diffusion tensor imaging to assess white matter microstructural integrity.
Lower fractional anisotropy generally indicates reduced white matter integrity.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Mean Diffusivity
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Mean diffusivity will be measured using diffusion tensor imaging to assess white matter microstructural changes.
Higher mean diffusivity generally indicates greater microstructural disruption.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Radial Diffusivity
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Radial diffusivity will be measured using diffusion tensor imaging to assess white matter microstructural changes.
Higher radial diffusivity generally indicates greater white matter microstructural abnormality.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Default Mode Network Functional Connectivity
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Functional connectivity of the default mode network will be assessed using resting-state functional MRI to evaluate AD-related brain network function.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Salience Network Functional Connectivity
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Functional connectivity of the salience network will be assessed using resting-state functional MRI to evaluate AD-related brain network function.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Amplitude of Low-Frequency Fluctuations
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Amplitude of low-frequency fluctuations will be measured using resting-state functional MRI to assess local spontaneous neuronal activity.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Regional Homogeneity
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Regional homogeneity will be measured using resting-state functional MRI to assess local synchronization of neuronal activity.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Blood Neurofilament Light Chain Concentration
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Neurofilament light chain concentration in blood will be measured as a biomarker of neuronal injury and neurodegeneration.
Higher concentrations generally indicate greater neuronal injury.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Aβ42 Concentration in Blood or Cerebrospinal Fluid
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Aβ42 concentration in blood or cerebrospinal fluid will be measured as an Alzheimer's disease-related amyloid biomarker.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Aβ40 Concentration in Blood or Cerebrospinal Fluid
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Aβ40 concentration in blood or cerebrospinal fluid will be measured as an Alzheimer's disease-related amyloid biomarker.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Aβ42/Aβ40 Ratio in Blood or Cerebrospinal Fluid
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
The Aβ42/Aβ40 ratio in blood or cerebrospinal fluid will be measured as an Alzheimer's disease-related amyloid biomarker.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Phosphorylated Tau 181 Concentration in Blood or Cerebrospinal Fluid
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Phosphorylated tau 181 concentration in blood or cerebrospinal fluid will be measured as a biomarker of tau pathology in Alzheimer's disease.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
Phosphorylated Tau 217 Concentration in Blood or Cerebrospinal Fluid
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Phosphorylated tau 217 concentration in blood or cerebrospinal fluid will be measured as a biomarker of tau pathology in Alzheimer's disease.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
CIBIC-plus Score
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
The Clinician's Interview-Based Impression of Change Plus Caregiver Input is a semi-structured interview tool used to assess global clinical change in patients with dementia after treatment.
The score ranges from 1 to 7, with 1 indicating very much improved, 4 indicating no change, and 7 indicating very much worsened.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
|
MMSE Total Score
Időkeret: The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Mini-Mental State Examination (MMSE): A validated 30-point cognitive screening tool evaluating domains including orientation, memory, attention, language, and visuospatial abilities.
Rationale: The dual assessment leverages: CIBIC-plus for holistic, clinician-judged disease progression (anchored to baseline severity).
MMSE for quantifiable tracking of specific cognitive deficits.
|
The 0th、 4th 、8th and 12th week after taking Silkworm Silkworm pupa powder
|
Együttműködők és nyomozók
Szponzor
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Becsült)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
- Neurológiai megnyilvánulások
- Agyi betegségek
- Központi idegrendszeri betegségek
- Idegrendszeri betegségek
- Neuromuszkuláris megnyilvánulások
- Mentális zavarok
- Patológiás folyamatok
- Patológiai állapotok, anatómiai
- Neurokognitív zavarok
- Elmebaj
- Tauopathies
- Neurodegeneratív betegségek
- Izomsorvadás
- Sorvadás
- Kóros állapotok, jelek és tünetek
- Jelek és tünetek
- Törékenység
- Alzheimer-kór
- Sarcopenia
- Aszténia
Egyéb vizsgálati azonosító számok
- 2026-063(L)-F1
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .